Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALYST vs POMBILITI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
Multiple myeloma (in combination with dexamethasone) in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,AIDS-related Kaposi sarcoma (in patients with AIDS-related Kaposi sarcoma who have failed highly active antiretroviral therapy [HAART] or are intolerant to HAART)
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
500 mg orally twice daily
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Pomalidomide is primarily metabolized by cytochrome P450 (CYP) 1A2 and CYP3A4. It also undergoes hydroxylation and subsequent glucuronidation. Minor pathways include CYP2C19 and CYP2D6.
Primarily metabolized by CYP3A4, CYP2C8, and CYP2C9; also undergoes glucuronidation. The active metabolite, GFT505, is formed via hydrolysis.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
33% bound to human plasma proteins, predominantly to albumin.
>99% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 120 L (1.7 L/kg for a 70 kg individual), indicating extensive tissue distribution beyond plasma volume.
Volume of distribution is approximately 2000 L (>25 L/kg), indicating extensive extravascular distribution and tissue binding.
Oral bioavailability is approximately 73% (range: 66-81%). Administration with a high-fat meal decreases Cmax by 36% and AUC by 26% relative to fasting; therefore, take on an empty stomach.
Oral bioavailability is approximately 25% (range 15–35%) due to first-pass metabolism; may increase with high-fat meal.
For Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: reduce dose to 3 mg once daily; Cr Cl <30 m L/min: not recommended (no dose established).
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 250 mg twice daily; GFR <15 m L/min or dialysis: 250 mg once daily
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 3 mg once daily; Child-Pugh C: reduce dose to 2 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended
Safety and efficacy not established in pediatric patients; no standard dosing.
Weight <40 kg: 10 mg/kg orally twice daily (max 500 mg/dose); Weight ≥40 kg: 500 mg twice daily
No specific dose adjustment based on age alone; monitor for toxicity and adjust based on renal function as per adult recommendations.
No specific adjustment required; monitor renal function and consider age-related decline in GFR
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM. Pomalidomide is contraindicated in pregnant women because it can cause severe birth defects or death to an unborn baby. Females of reproductive potential must avoid pregnancy during treatment and for at least 4 weeks after the last dose. Pomalidomide is only available through a restricted distribution program called the POMALYST REMS program. Additionally, pomalidomide significantly increases the risk of venous and arterial thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke). Thromboprophylaxis is recommended.
None.
Embryo-fetal toxicity: Can cause fetal harm; females of reproductive potential must use effective contraception and avoid pregnancy. Males should avoid donating sperm.,Thromboembolism: Increased risk of venous and arterial thromboembolic events; thromboprophylaxis recommended.,Hematologic toxicity: Neutropenia and thrombocytopenia are common; monitor blood counts regularly.,Hepatotoxicity: Can cause elevated liver enzymes and hepatic failure; monitor liver function tests.,Cardiac toxicity: Increased risk of heart failure, myocardial infarction, and atrial fibrillation.,Hypersensitivity reactions: Including angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis; discontinue if severe reaction occurs.,Tumor lysis syndrome: Monitor patients at risk.,Interference with oral contraceptives: May reduce efficacy of oral contraceptives; consider additional non-hormonal contraception.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests before and during treatment.,Myopathy: Risk of muscle injury; assess creatine kinase if muscle symptoms occur.,Gallbladder-related events: Increased risk of cholelithiasis and cholecystitis.,Fetal risk: Based on animal data, may cause fetal harm; advise effective contraception in females of reproductive potential.,Renal impairment: Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Pregnancy,Hypersensitivity to pomalidomide or any component of the formulation
Hypersensitivity to elafibranor or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No specific dietary restrictions otherwise; take with or without food. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid alcohol due to increased risk of liver toxicity.
No known food interactions. Maintain a balanced diet as recommended by a healthcare provider. There are no specific dietary restrictions required with Pombiliti.
Pomalidomide is an immunomodulatory drug (IMi D) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth defects or embryo-fetal death. Fetal exposure during any trimester can cause major congenital malformations, including limb defects, craniofacial anomalies, and cardiovascular abnormalities. Use in females of reproductive potential requires negative pregnancy testing before treatment, and use of two effective contraceptive methods during therapy and for 4 weeks after discontinuation. Pregnancy testing frequency: weekly during first month, then every 2-4 weeks if regular cycles, or every 2 weeks if irregular cycles.
Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show embryolethality and teratogenicity at subclinical doses.
It is unknown whether pomalidomide is excreted in human milk. Due to the potential for serious adverse reactions in breastfeeding infants, women should not breastfeed during treatment with pomalidomide. No M/P ratio is available.
No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression, myelosuppression), breastfeeding is not recommended during therapy and for at least 3 months after last dose.
Pomalidomide is contraindicated in pregnancy; no dose adjustments are applicable because use during pregnancy is not recommended. If exposure occurs, the manufacturer recommends immediate discontinuation and referral to a teratology specialist. No pharmacokinetic studies on pregnancy-related dose adjustments exist.
No dose adjustment recommendations are possible; Pombiliti is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not studied due to contraindication. No specific dosing guidelines exist for pregnant patients.
Pomalidomide is an immunomodulatory drug used in multiple myeloma after prior therapies including lenalidomide and bortezomib. Requires baseline and periodic CBCs, liver and renal function tests. High risk for venous thromboembolism; prophylaxis with aspirin or anticoagulation recommended. Contraindicated in pregnancy due to severe teratogenicity, necessitating REMS program. Dose adjust for renal impairment (Cr Cl <45 m L/min) and hepatic impairment (Child-Pugh C). Monitor for tumor lysis syndrome, especially in patients with high tumor burden.
Pombiliti (cipaglucosidase alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy for Pompe disease. Do not confuse with alglucosidase alfa (Myozyme/Lumizyme). Requires premedication with antihistamines and antipyretics due to risk of infusion-associated reactions (IARs). Monitor for anaphylaxis, particularly during initial infusions. Administer by IV infusion over approximately 4 hours. Use a low-protein-binding infusion set with an in-line low-protein-binding filter. May cause rapid deterioration in patients with cardiac hypertrophy; monitor cardiac function before and during treatment.
Pomalidomide is a chemotherapy drug that helps treat multiple myeloma by targeting cancer cells.,Do not take if pregnant or planning to become pregnant; use effective contraception during treatment and for 4 weeks after stopping.,Do not breastfeed while taking pomalidomide.,Report any signs of bleeding, bruising, fever, shortness of breath, or chest pain immediately.,Take exactly as prescribed; do not break, chew, or crush capsules; swallow whole with water.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Avoid live vaccines while on this medication.,Store at room temperature away from moisture and heat.,Keep all appointments for blood tests and other monitoring.,Inform all healthcare providers that you are taking pomalidomide.
Inform your healthcare provider immediately if you experience hives, itching, difficulty breathing, swelling, chest tightness, or fever during or after the infusion.,You may receive premedications (such as antihistamines and acetaminophen) before your infusion to reduce the risk of allergic reactions.,Do not miss your scheduled infusions; regular treatment is necessary to manage Pompe disease.,Report any new or worsening muscle weakness, breathing difficulties, or heart-related symptoms.,Keep a list of all medications you take, including over-the-counter drugs and supplements, and share it with your doctor.,Pombiliti is not a cure; it is an enzyme replacement therapy to reduce symptoms and slow disease progression.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALYST vs POMBILITI, answered by our medical review team.
POMALYST is a Immunomodulatory Agent that works by Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.. POMBILITI is a Immunomodulatory Agent that works by POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALYST and POMBILITI depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALYST is: 4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.. The standard adult dose of POMBILITI is: 500 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALYST and POMBILITI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALYST is classified as Category C. Pomalidomide is an immunomodulatory drug (IMiD) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth de. POMBILITI is classified as Category C. Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.